Muhammet Özbilen: Is the IV Iron Given to Hospitalized Patients Sufficient?
Muhammet Özbilen, Associate Professor Doctor at Ordu University, shared a post on LinkedIn about a recent article by Joséphine A. Cool et al. published in AJH, adding:
“Is the IV iron given to hospitalized patients sufficient?
A paper published last month in the American Journal of Hematology paints a vivid picture.
The investigation was carried out at Harvard Medical School’s training hospital.
- More than 200,000 hospital admissions from 5 years were studied.
- Only 31.5% of anemic individuals had their iron levels checked.
- Only half (54%) of patients with iron deficiency anemia (IDA) were given iron supplements.
- The calculated median iron deficiency in patients receiving IV iron was 1,847 mg, while the median amount provided was only 500 mg.
So ‘Mind the Gap’ expresses just this: there is a 1,364 mg difference in the IV iron dose provided.
The cause for this big disparity can be described as follows:
- Iron measurements are commonly neglected when anemia is not the main reason for admission.
- The majority of DEA patients in this investigation were normocytic (median MCV: 86), contrary to expectations of microcytosis.
- Ferric gluconate is the most often used IV iron formulation with a low daily maximum dose. However, it is insufficient for non-dialysis patients and requires numerous doses.
- The present hospital treatment approach prioritizes acute stabilization over chronic disease management.
However, appropriate iron therapy has been shown to normalize hemoglobin levels within 8 weeks, reducing the need for outpatient IV iron.
Conclusion: DEA is underdiagnosed and undertreated in the inpatient context. To address this, physician education and system-level interventions are required.”
Title: Mind the Gap: Underdosing of Intravenous Iron in a Hospitalized Patient Population With Iron-Deficiency Anemia
Authors: Joséphine A. Cool, Linnea M. Wilson, Justine Blum, Jason A. Freed, Shoshana J. Herzig

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?